共 37 条
Late Local Recurrence of Bone Giant Cell Tumors Associated with an Increased Risk for Malignant Transformation
被引:13
作者:
Tsukamoto, Shinji
[1
]
Righi, Alberto
[2
]
Mavrogenis, Andreas F.
[3
]
Akahane, Manabu
[4
]
Honoki, Kanya
[1
]
Tanaka, Yasuhito
[1
]
Donati, Davide Maria
[5
]
Errani, Costantino
[5
]
机构:
[1] Nara Med Univ, Dept Orthopaed Surg, Kashihara, Nara 6348521, Japan
[2] IRCCS Ist Ortoped Rizzoli, Dept Pathol, I-40136 Bologna, Italy
[3] Natl & Kapodistrian Univ Athens, Sch Med, Dept Orthopaed 1, Athens 15562, Greece
[4] Natl Inst Publ Hlth, Dept Hlth & Welf Serv, Wako, Saitama 3510197, Japan
[5] IRCCS Ist Ortoped Rizzoli, Dept Orthopaed Oncol, I-40136 Bologna, Italy
来源:
关键词:
giant cell tumor of bone;
denosumab;
surgery;
metastasis;
malignant transformation;
recurrence;
chemotherapy;
MEGAVOLTAGE RADIATION-THERAPY;
OPEN-LABEL;
RECEIVING TREATMENT;
DENOSUMAB;
SAFETY;
RADIOTHERAPY;
EFFICACY;
PATIENT;
SARCOMA;
D O I:
10.3390/cancers13143644
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
Simple Summary In giant cell tumor of bone (GCTB), an intermediate malignant bone tumor, approximately 4% of cases can undergo malignant transformation. We analyzed risk factors for malignant transformation of GCTB treated without radiotherapy and retrospectively reviewed medical files of 461 patients with GCTB of the extremities who had undergone surgery alone, with no radiotherapy or denosumab therapy. Malignant transformation occurred in 15 of 461 patients (3.3%) at a median follow-up period of 192 months. The median follow-up duration was 89.4 months. Multivariate analysis revealed that local recurrence was an independent prognostic factor for unfavorable malignant transformation. The interval between the last surgery to local recurrence and malignant transformation was longer than that to local recurrence of benign GCTB, with a median of 15.2 (IQR, 5.2-25.4) years versus 1.3 (IQR, 0.8-2.6) months, respectively (p < 0.001). Late local recurrence of GCTB is associated with a higher risk of malignant transformation. In giant cell tumor of bone (GCTB), an intermediate malignant bone tumor, approximately 4% of all cases undergo malignant transformation. Accordingly, we analyzed risk factors for malignant transformation of GCTB treated without radiotherapy. We retrospectively reviewed medical records of 530 patients with GCTB of the extremities, admitted and treated at two institutions between January 1980 and December 2019. Overall, 4 patients with primary malignant GCTB, 4 patients with missing data, 3 patients with a history of radiotherapy, 22 patients with a follow-up of less than 6 months, and 36 patients who received denosumab were excluded. Accordingly, 461 patients were included for further analysis. Malignant transformation was observed in 15 of 461 patients (3.3%) at a median follow-up period of 192 months. The median follow-up duration was 89.4 months. Multivariate analysis revealed that local recurrence was an independent prognostic factor for unfavorable malignant transformation (Hazard ratio [HR], 11.33; 95% confidence interval [CI] 2.33-55.13; p = 0.003 for once versus none and HR, 11.24; 95% CI, 1.76-71.96; and p = 0.011 for twice or more versus none). The interval between the last surgery to local recurrence and malignant transformation was longer than that to local recurrence of benign GCTB, with a median of 15.2 years (interquartile range [IQR], 5.2-25.4) versus 1.3 months (IQR, 0.8-2.6), respectively (p < 0.001). Late local recurrence of GCTB is associated with a higher risk of malignant transformation.
引用
收藏
页数:12
相关论文